Use of lipid conjugates in the treatment of conjunctivitis
In one embodiment, the invention provides a method of suppressing, inhibiting, preventing, or treating conjunctivitis in a subject, comprising the step of administering an effective amount of a lipid or phospholipid moiety bound via an ester or amide bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof to a subject with conjunctivitis.
1. A method of suppressing or inhibiting conjunctivitis in a subject comprising the step of contacting said subject with a compound represented by the structure of the general formula (I) or (II), and/or a pharmaceutical salt or a pharmaceutical composition thereof:
wherein
R 1 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
R 2 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
X is a physiologically acceptable monomer, dimer, oligomer or polymer; and
n is a number from 1 to 1000;
wherein if Y is nothing, the phospholipid moiety is directly linked to X via an amide bond and if Y is a spacer, the spacer is directly linked to X via an amide or an esteric bond and to the phospholipid moiety via an amide bond.
2. The method according to claim 1 , wherein said conjunctivitis is viral conjunctivitis.
3. The method according to claim 1 , wherein said conjunctivitis is bacterial conjunctivitis.
4. The method according to claim 1 , wherein said conjunctivitis is due to an allergen.
5. The method according to claim 1 , wherein said conjunctivitis is due to an irritant.
6. The method according to claim 1 , wherein said phospholipid moiety is phosphatidylethanolamine.
7. The method according to claim 6 , wherein said phosphatidylethanolamine is dipalmitoyl phosphatidylethanolamine.
8. The method according to claim 6 , wherein said phosphatidylethanolamine is dimyristoyl phosphatidylethanolamine.
9. The method according to claim 1 , wherein said physiologically acceptable monomer, dimer, oligomer, or polymer is carboxymethylcellulose.
10. The method according to claim 1 , wherein R 1 and/or R 2 are palmitic acid moieties.
11. The method according to claim 1 , wherein R 1 and/or R 2 are myristic acid moieties.
12. The method according to claim 1 , wherein X is hyaluronic acid.
13. The method according to claim 1 , wherein X is heparin.
14. The method according to claim 1 , wherein X is chondroitin sulfate.
15. The method according to claim 1 , wherein X is a glycosaminoglycan.
16. The method according to claim 1 , wherein X is selected from the group of molecules consisting of polygeline, hydroxyethylstarch, dextran, aspirin, albumin, alginate, polyaminoacid, polyethylene glycol, lactobionic acid, acetylsalicylate, cholesteryl-hemmisuccinate, maltose, cholic acid, polycarboxylated polyethylene glycol, and glutaryl.
17. The method according to claim 1 , wherein said phospholipid moiety is phosphatidylserine.
18. The method according to claim 17 , wherein said phosphatidylserine is dipalmitoyl phosphatidylserine.
19. The method according to claim 17 , wherein said phosphatidylserine is dimyristoyl phosphatidylserine.
20. The method according to claim 1 , wherein n is a number from 2 to 1000.